ReviewFrontiers in pharmacology2017
The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery.
Review in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Oncopig bladder cancer cells recapitulate human bladder cancer treatment responsesFrontiers in oncology · 2024Article
- Validation of airway porcine epithelial cells as an alternative to human in vitro preclinical studies.Scientific reports · 2023Article
- The Oncopig as an Emerging Model to Investigate Copper Regulation in Cancer.International journal of molecular sciences · 2022Review
- Employing Novel Porcine Models of Subcutaneous Pancreatic Cancer to Evaluate Oncological Therapies.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Porcine pancreatic ductal epithelial cells transformed with KRASScientific reports · 2021Article
- Perspective: Humanized Pig Models of Bladder Cancer.Frontiers in molecular biosciences · 2021Article
- Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do.Frontiers in bioengineering and biotechnology · 2020Review
- The Melding of Drug Screening Platforms for Melanoma.Frontiers in oncology · 2019Review
- Editorial: Building Strategies for Porcine Cancer Models.Frontiers in genetics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. PDD, also known as phenotypic screening, consists of screening potential compounds in either
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.